PharmaNet Professionals Addressing Challenges of Biopharmaceutical Research & Development During Drug Information Association M
June 19 2006 - 7:30AM
Business Wire
Celebrating the 10th Anniversary of the Company, Representatives of
PharmaNet Continue Their Long History of Support for DIA and Its
Membership Scientists and clinicians representing PharmaNet (a
division of SFBC International) (NASDAQ: SFCC) are addressing many
of the challenges facing the biopharmaceutical research and
development industry at several sessions scheduled to take place at
the upcoming Drug Information Association (DIA) annual meeting in
Philadelphia, Pennsylvania (June 18 - 22, 2006). "Many of our
PharmaNet employees have been involved with the DIA throughout
their careers. In each of our past ten years I have been especially
proud of the number and quality of the presentations given by our
staff at the annual conference," said Jeffrey P. McMullen,
president and chief executive officer, PharmaNet. "Covering topics
including clinical research methodologies, patient recruitment and
retention, enhancing product value, regulatory strategies, training
and strategic clinical trial development, some of our most talented
individuals will be sharing their perspectives with participants at
the DIA meeting. We are honored to have these opportunities. As
well, we are very pleased to continue our long heritage of support
for the DIA meeting." Among the PharmaNet professionals scheduled
to present are: -- Peggy Schrammel, executive director, late phase
development - Ms. Schrammel is scheduled to chair a session
entitled, "Demonstrating Product Value: Three Unique Perspectives"
and is a speaker of a session entitled, "Strategies for Outsourcing
and Managing Late Phase Trials Using Naive Sites." She has designed
and managed the implementation of late-phase programs to
demonstrate product value for numerous clients. At PharmaNet, Ms.
Schrammel ensures that Late Phase Development Division programs
adhere to the highest standards of scientific integrity and
regulatory compliance while meeting marketing objectives. --
Duu-Gong Wu, PhD, executive director, PharmaNet consulting division
- Dr. Wu is a biochemist and molecular biologist whose professional
experience includes senior-level positions at the Food and Drug
Administration Division of New Drug Chemistry II, with the Center
for Drug Evaluation and Research. Dr. Wu is scheduled to speak in a
session entitled, "Regulatory Considerations on the Development of
Botanical Drug Products in the U.S." -- Bryce Bartruff, RN, MBA,
PhD, manager, clinical research - Mr. Bartruff has more than 13
years of relevant clinical experience, including positions as staff
nurse, clinical research associate, senior clinical research
scientist and now, manager of clinical research. At PharmaNet, Mr.
Bartruff has oversight of the Infectious Disease Division's efforts
regarding subject recruitment and retention. He is scheduled to
chair a session entitled, "Reaching Subject Recruitment and
Retention Goals." -- Michael E. Laird, senior vice president,
worldwide business development - Mr. Laird has more than 20 years
of pharmaceutical and contract research industry experience and has
held senior-level positions at Smith, Kline & French; Marion
Merrell Dow; Proctor & Gamble Pharmaceuticals; and Kendle. As
head of PharmaNet's global business development, Mr. Laird has
daily involvement in leveraging professional resources as a
differentiator among contract research organizations and is
scheduled to chair a session entitled, "Intellectual Human Capital
in Contract Research: Is the Market There?" -- Hani Zaki, MPH, MBA,
vice president, business development - Mr. Zaki is scheduled to
chair a session entitled, "Strategies for Outsourcing and Managing
Late Phase Trials Using Naive Sites." Mr. Zaki has worked in both
clinical research and pharmaceutical marketing since 1982,
including 11 years of clinical research in oncology, infectious
diseases, allergy and pulmonology, and CNS. His experience includes
service with Schering-Plough, Bristol-Myers (now BMS), and
Rhone-Poulenc Rorer (now Sanofi-Aventis). Mr. Zaki headed the U.S.
anti-infective clinical operations group for RPR, with
responsibilities for program implementation and resource
allocation. -- Janet Zimmerman, MSN, senior director, training
services - Ms. Zimmerman has facilitated more than 200 workshops
and courses for clinical research personnel. During a healthcare
career spanning more than 25 years, she has held positions as a
research nurse; clinical research associate (CRA); trainer and
course developer; as well as CRA training manager and is scheduled
to speak at two different DIA sessions including, "GCP Training
Around the Globe: Similarities and Differences and Using ADDIE to
Strategically Analyze and Evaluate Your Training Program." She is
also scheduled to co-present at a session entitled, "Online
Learning: Managing the Implementation Process" with PharmaNet
colleague Robert Morrison, RN, manager, training services. Mr.
Morrison has more than 26 years of clinical experience, including
the last 7 years in contract research. His previous titles have
included therapeutic research associate in oncology and cardiology,
senior clinical research associate, and project manager. -- Jim
Downhower, MSE, senior director, IT development - Mr. Downhower has
more than 15 years of experience with computer systems, including 9
years in clinical-development information technology (IT), and Kim
Sanford, director, clinical data management with more than 15 years
of clinical experience, including positions as CRF data scientist,
senior clinical data analyst, and several positions of increasing
responsibility in clinical data management, are scheduled to
co-present at a session entitled, "Hybrid Data Capture Strategies."
About PharmaNet/SFBC International, Inc. PharmaNet is the late
stage division of SFBC International, Inc. As an international drug
development services company, SFBC offers a comprehensive range of
clinical development, clinical and bioanalytical laboratory, and
consulting services to the branded pharmaceutical, biotechnology,
generic drug and medical device industries. The Company has more
than 30 offices, facilities and laboratories with more than 2,000
employees strategically located throughout the world. PharmaNet
represents over half of the Company. PharmaNet is dedicated to
providing the highest level of client satisfaction and
industry-leading expertise to the pharmaceutical, biotechnology,
medical device, and combined-product industries. Founded in 1996,
PharmaNet today continues to deliver a positive outsourcing
experience through its founding principles. For more information,
visit www.sfbci.com and www.pharmanet.com. Forward-Looking
Statements Certain statements made in this press release are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 (the "Act"). Additionally
words such as "seek," "intend," "believe," "plan," "estimate,"
"expect," "anticipate" and other similar expressions are
forward-looking statements within the meaning of the Act. Some or
all of the results anticipated by these forward-looking statements
may not occur. Factors that could cause or contribute to such
differences include, but are not limited to, our ability to
leverage the strong reputation of PharmaNet, whether adverse
publicity relating to SFBC's Miami operations causes clients to
select competitors, not only for early stage branded clinical
trials but also for other aspects of SFBC's business; SFBC's
ability to resolve open issues relating to its Miami property
including whether it can successfully appeal and/or enjoin the
Miami-Dade County Unsafe Structures Board ruling and any related
fines or expenses if we are unsuccessful, the associated costs and
expenses with discontinuing the Company's operations in Miami and
Ft. Myers, whether a building permit will be issued, whether SFBC
will prevail in the pending land lease litigation; continued
adverse publicity related to actions of the United States Senate
Finance Committee; developments with respect to the SEC's inquiry
and securities class action lawsuits and derivative lawsuits;
SFBC's assessment of its current FDA inspections; SFBC's ability to
successfully achieve and manage the technical requirements of
specialized clinical trial services, while complying with
applicable rules and regulations; regulatory changes; changes
affecting the clinical research industry; a reduction of
outsourcing by pharmaceutical and biotechnology companies; SFBC's
ability to compete internationally in attracting clients in order
to develop additional business; cancellation of contracts; SFBC's
ability to retain and recruit new employees; SFBC's clients'
ability to provide the drugs and medical devices used in its
clinical trials; SFBC's future stock price; SFBC's financial
guidance; and the national and international economic climate as it
affects drug development operations. Further information can be
found in SFBC's risk factors contained in its Form 10-K filed with
the SEC in 2006 and other filings with the Securities and Exchange
Commission.
Sfbc (NASDAQ:SFCC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sfbc (NASDAQ:SFCC)
Historical Stock Chart
From Jul 2023 to Jul 2024